(Q37593466)

21 August 2017

1 reference

title

Enhancing the efficacy of cancer vaccines in urologic oncology: new directions (English)

1 reference

21 August 2017

Sergei Kusmartsev

1

1 reference

21 August 2017

Johannes Vieweg

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

8 September 2009

1 reference

21 August 2017

published in

Nature Reviews Urology

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

540-549

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2009.177

21 August 2017

exact match

0 references

cites work

Future directions for vaccine-based therapies

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Technology Insight: vaccine therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cancer immunotherapy: breaking the barriers to harvest the crop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

The promise of cancer vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Taking dendritic cells into medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Immunosuppressive networks in the tumour environment and their therapeutic relevance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Reversal of tumor-mediated immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Immunosuppressive strategies that are mediated by tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Local and systemic immune suppression in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cancer-related inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

The role of myeloid cells in the promotion of tumour angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Myeloid-derived suppressor cells: linking inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Mechanisms of immune dysfunction in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Control of T-cell activation by CD4+ CD25+ suppressor T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Regulatory T cells and treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Prostaglandins and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Targeting prostaglandin E EP receptors to inhibit metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Inhibition of T cell proliferation by macrophage tryptophan catabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Angiogenesis as a therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

31 March 2020

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Combination targeted therapy in advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Bevacizumab for patients with metastatic renal cancer: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Looking to the future for erectile dysfunction therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Certified professionals: CD4(+)CD25(+) suppressor T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Regulatory T cells and immune tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Optimizing denileukin diftitox (Ontak) therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.177

Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.

31 March 2020

1 reference

12 December 2020

Immunotherapy for advanced prostate cancer

1 reference

12 December 2020

All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

1 reference

12 December 2020

Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

1 reference

12 December 2020

Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo

1 reference

12 December 2020

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2009.177

1 reference

21 August 2017

1 reference